The ACIP release guidelines for the 2020-2021 vaccination recommendations; In COVID, there's developments in convalescent plasma authorization; A 15 minute test; And ethnobotanist's give a stark warning concerning a plant that some are touting as a cure; In other news an intrauterine device gains expanded approval; Label update for hydrochlorothiazide.

Treatment shows promise for patients who had pneumonia associated with COVID-19; A COVID-19 test that may have given inaccurate results; Neck gaiters as face masks may actually spread the virus; Drug applications are halted by the FDA; And Narcan has it's shelf life extended. Also, we recap drug pipeline news from the past week.

Remdesivir is submitted; New opioid approved by FDA; A new Spinal Muscular Atrophy treatment; A sublingual epinephrine treatment; and the latest on Biogen's investigational Alzheimer disease treatment.

This week there's more COVID vaccine developments; A first-of-its-kind trial assessing a drug for preventing COVID in long term care facilities; A cannabidiol treatment gains another indication; Depression treatment gains indication for major depressive disorders with acute suicidal ideation or behavior; And the FDA requests more information for their review of the peanut allergy treatment, Viaskin.

It's been an important week with big developments in potential COVID-19 vaccines; News on how steroid therapy may help some COVID patients; There's results from the Actemra trial in COVID pneumonia patients; News that sputum samples may be just as effective as nasopharyngeal samples for detecting sars-cov-2; And researchers have linked vaccination to reduced risks of Alzheimer disease.

This week: The government makes a $1.95 billion deal for a COVID-19 vaccine; Promising data from the Oxford vaccine trial; The CDC retakes control of COVID-19 data; Novel calcineurin inhibitor for lupus nephritis gets priority review; And there's new treatment for narcolepsy.

This week; Significant moves in COVID-19 vaccine development; Research finds a link between PPI use and increased risk of COVID-19; We look at remdesivir's efficacy in severe COVID-19 cases; And several Company's recall their metformin extended release tablets.

The discontinuation of a trial investigating a potential COVID-19 treatment; A safety alert for toxic hand sanitizers; Vaccine guidance in the time of the pandemic; And new treatments in HIV and myelodysplastic syndromes.

This week on the Pod: The FDA issues guidance for COVID-19 vaccine development; Accuracy in COVID-19 antibody testing; How statins may improve outcomes for hospitalized COVID-19 patients; and in non-COVID-related news there's a new drug approvals in breast cancer and Dravet syndome.

This week on the Pod: Over-the-counter med recalls; a nasal spray approved for diabetic gastroparesis; reports of an uptick in penicillin-, ciprofloxacin-resistant meningococci; and in pandemic-related news, a possible inhaled version of remdesivir, and colchicine as a potential treatment.